Immunocore Holdings plc (IMCR)

Sector: Healthcare
Industry: Biological Products, (No Diagnostic Substances)
Country: United Kingdom
Exchange: NASDAQ
Market cap: $1.66B

Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.

Latest financial period: June 30, 2026
Filed with the SEC: August 6, 2026
Estimated earnings date: November 5, 2026

Menu

Home

Compare

Next Earnings Reports

How this site works

Terms of use

About